These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 29703236)
1. High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis. Hatano Y; Fukuda S; Makino H; Tomita H; Morishige KI; Hara A Diagn Pathol; 2018 Apr; 13(1):24. PubMed ID: 29703236 [TBL] [Abstract][Full Text] [Related]
2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
3. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma]. Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294 [No Abstract] [Full Text] [Related]
4. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388 [TBL] [Abstract][Full Text] [Related]
5. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors]. Wen J; Shi JL; Shen DH; Chen YX; Song QJ Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451 [TBL] [Abstract][Full Text] [Related]
9. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature. Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633 [TBL] [Abstract][Full Text] [Related]
10. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. Sherman-Baust CA; Kuhn E; Valle BL; Shih IeM; Kurman RJ; Wang TL; Amano T; Ko MS; Miyoshi I; Araki Y; Lehrmann E; Zhang Y; Becker KG; Morin PJ J Pathol; 2014 Jul; 233(3):228-37. PubMed ID: 24652535 [TBL] [Abstract][Full Text] [Related]
11. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714 [TBL] [Abstract][Full Text] [Related]
12. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma. Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751 [TBL] [Abstract][Full Text] [Related]
13. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. Lee Y; Miron A; Drapkin R; Nucci MR; Medeiros F; Saleemuddin A; Garber J; Birch C; Mou H; Gordon RW; Cramer DW; McKeon FD; Crum CP J Pathol; 2007 Jan; 211(1):26-35. PubMed ID: 17117391 [TBL] [Abstract][Full Text] [Related]
14. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. Wu RC; Wang P; Lin SF; Zhang M; Song Q; Chu T; Wang BG; Kurman RJ; Vang R; Kinzler K; Tomasetti C; Jiao Y; Shih IM; Wang TL J Pathol; 2019 May; 248(1):41-50. PubMed ID: 30560554 [TBL] [Abstract][Full Text] [Related]
15. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067 [TBL] [Abstract][Full Text] [Related]
16. Na K; Sung JY; Kim HS Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446 [TBL] [Abstract][Full Text] [Related]
17. The genomic trajectory of ovarian high-grade serous carcinoma can be observed in STIC lesions. Cheng Z; Ennis DP; Lu B; Mirza HB; Sokota C; Kaur B; Singh N; Le Saux O; Russo G; Giannone G; Tookman LA; Krell J; Barnes C; McDermott J; McNeish IA J Pathol; 2024 Sep; 264(1):42-54. PubMed ID: 38956451 [TBL] [Abstract][Full Text] [Related]
18. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341 [TBL] [Abstract][Full Text] [Related]
19. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838 [TBL] [Abstract][Full Text] [Related]
20. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer. Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]